Resources
15 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 3/3/2021 (updated 4/5/2024)
The National Governors Association and the American Correctional Association recently released a new toolkit on "Expanding Access to Medications for Opioid Use Disorder in Corrections and Community Settings: A Roadmap for States to Reduce Opioid Use Disorder for People in the Justice System."
This roadmap highlights existing state efforts and serves as a policy development tool for Governors and state officials seeking to improve coordination and bolster existing efforts across state agencies to address OUD among people involved in the justice system by expanding access to evidence-based medications. The following are key steps for supporting MOUD in corrections settings.
Posted 2/18/2021 (updated 4/4/2024)
Opioid use disorder (OUD), a chronic disease, is a major public health problem. Despite availability of effective treatment, too few people receive it and treatment retention is low. Understanding barriers and facilitators of treatment access and retention is needed to improve outcomes for people with OUD.
In this study we sought to assess 3-month outcomes from a patient-centered practice that included MAT with buprenorphine or naltrexone plus the option to participate in psychosocial treatments. The psychosocial treatments included case management, psychotherapy, peer recovery groups such as Narcotics Anonymous or Smart Recovery, or peer support through a local harm reduction program.
Posted 12/9/2020 (updated 4/3/2024)
Detailed risk benefit assessment of medications, settings and patient outcomes. These guidelines were developed in response to a resolution from the United Nations Economic and Social Council (ECOSOC), “to develop and publish minimum requirements and international guidelines on psychosocially assisted pharmacological treatment of persons dependent on opioids”
Posted 7/7/2021 (updated 4/2/2024)
In 2015, 33,091 persons in the United States died from an opioid-related drug overdose.The epidemic of opioid overdose deaths has led to expanding the use of naloxone in community settings by non–medically trained bystanders who are often people who use drugs (PWUD). Since 2013, illicitly manufactured fentanyl (IMF), fentanyl analogs, and other synthetic opioids have played an increasing role in overdose deaths in the United States. Illicitly manufactured fentanyl (IMF) prevalence has increased. However, there is uncertainty about naloxone dose(s) used by nonmedical bystanders to reverse opioid overdoses in the context of increasing IMF.
Posted 9/30/2020 (updated 3/29/2024)
This packet presents Implementation II grantees with tools and strategies to support implementation activities that expand the options for SUD/OUD services across the care spectrum, thereby helping rural residents in your community to prevent SUD/OUD, access treatment, and move toward recovery.
Posted 2/4/2020 (updated 3/28/2024)
How States are Responding to the Opioid Crisis: An Overview Webinar Presentation and Materials
Posted 5/22/2020 (updated 3/28/2024)
As a response to the ongoing opioid crisis, every US state has increased access to naloxone through a variety of expanded prescribing methods, such as standing orders or protocols. This reports examines the impact of a standing order for rural Georgia pharmacies.
Posted 5/13/2020 (updated 3/28/2024)
In recent years, much attention in the U.S. has been focused on the opioid crisis, which was responsible for nearly 46,000 overdose deaths in 2018. This crisis initially began to accelerate in the early 2000s with a steady rise in the abuse of prescription pain medications, and beginning around 2010, opioid deaths increasingly involved heroin. As of 2013, the ready availability of potent synthetic opioids such as fentanyl ushered in a new era of rapidly increasing opioid overdose deaths, with the total number of opioid deaths doubling between 2013 and 2018. Deaths involving synthetic opioids have continued to rise very rapidly, even as involvement of commonly prescribed prescription opioids and heroin has leveled off recently.
Posted 3/15/2024 (updated 3/28/2024)
Clinical experts from the Providers Clinical Support System (PCSS) created the Substance Use Disorder 101 Core Curriculum for Healthcare Professionals. With the addition of two new module topics, the 23 modules in this 2023 curriculum provide an overview of evidence-based practices in the prevention, identification, and treatment of substance use disorders and co-occurring medical and psychiatric conditions for a variety of populations.
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Mt. Vernon Square Room on Wednesday, March 4, 2020, at 4:15 PM